ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ocankitug

Also written as “CM326”, “CM326(formulation 1)” and “CM326(formulation 2)”.

Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.

Drug pageOcankitug: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 13, 202113 company-led studies, 5 open or runningLicense: Keymed → CSPC (JMT-Bio), Nov 2021Next primary completion: Jul 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciencesits history only81 open or runningphase 2since Dec 13, 2021Apr 8, 2021none ahead
CSPC Pharmaceutical Group54 open or runningphase 3since Jan 11, 2026Mar 6, 2023Jul 1, 2027phase 2 · NCT07418736
  • Named in CSPC Pharmaceutical Group’s own pipeline as CM326, phase 3, as of Aug 20, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 2021CSPC (JMT-Bio) licensed it from KeymedLicenseMainland China, in all uses since November 2024 (respiratory diseases before) · agreed · Keymed Biosciences (HKEX announcement)
  2. Mar 6, 2023First study: phase 2 study in Moderate to Severe AsthmaFirst studyNCT05774340 · 207 enrolled · China
  3. Feb 29, 2024Named ocankitugINNProposed as its International Nonproprietary Name in WHO's List 130 · before, CM326
  4. Jan 11, 2026Phase 3 study in Moderate to Severe AsthmaPhase 3 reachedNCT07372287 · 230 planned · China
  5. Feb 4, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07418736 · 318 planned · China
  6. Feb 12, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07420257 · 212 planned
  7. Apr 14, 2026Phase 1 study in Healthy SubjectsNCT07560033 · 192 planned

Ahead

  1. Jul 1, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07418736
  2. Oct 30, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07420257
  3. Dec 31, 2028Primary completion: phase 3 study in Moderate to Severe AsthmaNCT07372287

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07560033Healthy Subjects1Not yet recruitingOct 1, 2026192
NCT07420257Chronic Rhinosinusitis With Nasal Polyps3Not yet recruitingOct 30, 2028212
NCT07418736Pulmonary Disease, Chronic Obstructive · China2RecruitingJul 1, 2027318
NCT07372287Moderate to Severe Asthma · China3RecruitingDec 31, 2028230
NCT05774340Moderate to Severe Asthma · China2UNKNOWNJan 2025207

How it is read

Names in the registry

  • “CM326”, 10 entries
  • “CM326(formulation 1)”, 1 entry
  • “CM326(formulation 2)”, 1 entry
  • “CM326 injection”, 1 entry
  • “CM326 dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.